Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Pharmacokinetics, Safety and Tolerability of BI 671800 HEA Given Over 7 Days. A Randomised, Double Blind, Placebo Controlled Within Dose Groups Phase I Study in Healthy Male and Female Volunteers.

31 de outubro de 2013 atualizado por: Boehringer Ingelheim

Pharmacokinetics, Safety and Tolerability of BI 671800 HEA Given 200 mg b.i.d. or 400 mg b.i.d. Over 7 Days. A Randomised, Double Blind, Placebo Controlled Within Dose Groups Phase I Study in Healthy Male and Female Volunteers.

The main objectives of the multiple dose study are to investigate the safety, tolerability pharmacokinetics of BI 671800 HEA in healthy male and female volunteers following multiple oral administration of BI 671800

Visão geral do estudo

Status

Concluído

Condições

Tipo de estudo

Intervencional

Inscrição (Real)

24

Estágio

  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Ingelheim, Alemanha
        • 1268.59.1 Boehringer Ingelheim Investigational Site

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

21 anos a 50 anos (Adulto)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion criteria:

  1. Healthy males and females according to the following criteria: Based upon a complete medical history, including physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead electrocardiogram (ECG), clinical laboratory tests
  2. Age 21 to 50 years (incl.)
  3. Body Mass Index (BMI) 18.5 to 29.9 kg/m2 (incl.)
  4. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation

Exclusion criteria:

  1. Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance
  2. Any evidence of a clinically relevant concomitant disease
  3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  4. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  5. History of relevant orthostatic hypotension, fainting spells or blackouts
  6. Chronic or relevant acute infections
  7. History of relevant allergy or hypersensitivity (including allergy to drug or its excipients)
  8. Intake of drugs with a long half life (>24 h) within one month or less than 10 half-lives of the respective drug prior to first study drug administration
  9. Participation in another trial with an investigational drug within 2 months prior to administration or during the trial
  10. Smoker (more than 10 cigarettes or 3 cigars or 3 pipes daily)
  11. Alcohol abuse (average consumption of more than 20 g/day in females and 30 g/day in males) or positive alcohol test
  12. Drug abuse
  13. Blood donation (more than 100 mL within four weeks prior to day 1 of visit 2)
  14. Any laboratory value outside the reference range that is of clinical relevance, especially repeated Alanine transaminase (ALT), Aspartate transaminase (AST), Gamma-glutamyl-transferase (GGT), Alkaline phosphatase (ALP) or total bilirubin above upper limit of normal (ULN) at screening and not resolved before dosing.
  15. Inability to comply with dietary regimen of trial site
  16. Use of drugs which might reasonably influence the results of the trial or that prolong the QT/QTc interval within 10 days prior to administration or during the trial, and CYP2C8 substrates such as amiodarone, amodiaquine, paclitaxel, rosiglitazone, pioglitazone and repaglinide or CYP2C9 such as warfarin, tolbutamide, phenytoin, losartan, acenocoumarol within 1 month or six half lives (whichever is greater).
  17. Repeated demonstration of a QTc interval >450 ms, PR interval >230 ms or a QRS interval >120 ms; history of additional risk factors for torsade de pointes (e.g., heart failure, hypokalaemia, family history of Long QT Syndrome)

    For female subjects of childbearing potential only:

  18. Positive pregnancy test, pregnancy or planning to become pregnant during the study or within 2 months after study completion
  19. No adequate contraception during the study including three months before first dosing until 2 month after study completion, e.g. not any of the following: implants, injectables, combined hormonal contraceptives, intrauterine device, or surgical sterilisation (including hysterectomy). In addition to this, also a barrier method (e.g. condom) will be required, if the female is not surgically sterilised.
  20. Lactation

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: BI 671800 HEA medium dose
Tablet, oral administration with 240 mL of water for each treatment
High dose oral administration
Medium dose oral administration
Experimental: BI 671800 HEA high dose
2 Tablets, oral administration with 240 mL of water for each treatment
High dose oral administration
Medium dose oral administration
Comparador de Placebo: Placebo
Matching to HEA 200 mg tablets, oral administration
Matching to HEA 200 mg tablet, oral administration

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Prazo
Eventos adversos
Prazo: 12 semanas
12 semanas
Vital signs (pulse rate (PR))
Prazo: 12 weeks
12 weeks
Clinical laboratory test (clinical chemistry)
Prazo: 12 weeks
12 weeks
Clinical laboratory test (urinalysis)
Prazo: 12 weeks
12 weeks
Physical examination
Prazo: 12 weeks
12 weeks
Vital signs (blood pressure (BP))
Prazo: 12 weeks
12 weeks
12-lead ECG (electrocardiogram)
Prazo: 12 weeks
12 weeks
Clinical laboratory test (haematology)
Prazo: 12 weeks
12 weeks
Assessment of tolerability by investigator
Prazo: 12 weeks
12 weeks

Medidas de resultados secundários

Medida de resultado
Prazo
Cmax (maximum plasma concentration of BI 671800 or BI 600957)
Prazo: up to day 12 post treatment
up to day 12 post treatment
tmax (time from dosing until maximum concentration of BI 671800 or BI 600957 is measured)
Prazo: up to day 12 post treatment
up to day 12 post treatment
AUC0-infinity (area under the plasma concentration-time curve of BI 671800 or BI 600957 from time of dosing extrapolated to infinity)
Prazo: up to day 12 post treatment
up to day 12 post treatment
AUCτ,1 (area under the plasma concentration-time curve of BI 671800 or BI 600957 for the complete dosing interval τ)
Prazo: up to day 12 post treatment
up to day 12 post treatment
AUC0-tz (area under the plasma concentration-time curve of BI 671800 or BI 600957 from time of dosing to time tz of last quantifiable concentration)
Prazo: up to day 12 post treatment
up to day 12 post treatment
Cmax,ss (maximum plasma concentration of BI 671800 or BI 600957 at steady state)
Prazo: up to day 12 post treatment
up to day 12 post treatment
tmax,ss (time from dosing until maximum concentration of BI 671800 or BI 600957 at steady state is measured)
Prazo: up to day 12 post treatment
up to day 12 post treatment
Cavg,ss (average measured plasma concentration of BI 671800 or BI 600957 at steady state)
Prazo: up to day 12 post treatment
up to day 12 post treatment
AUCτ,ss (area under the plasma concentration-time curve of BI 671800 or BI 600957 at steady state for the complete dosing interval τ)
Prazo: up to day 12 post treatment
up to day 12 post treatment
λz,ss (terminal rate constant of BI 671800 or BI 600957 in plasma at steady state)
Prazo: up to day 12 post treatment
up to day 12 post treatment
t1/2,ss (terminal half-life of BI 671800 or BI 600957 in plasma at steady state)
Prazo: up to day 12 post treatment
up to day 12 post treatment
MRTpo,ss (mean residence time of BI 671800 in the body at steady state after oral administration)
Prazo: up to day 12 post treatment
up to day 12 post treatment
CL/F,ss (apparent clearance of BI 671800 at steady state following oral administration)
Prazo: up to day 12 post treatment
up to day 12 post treatment
Vz/F,ss (apparent volume of distribution of BI 671800 during the terminal phase at steady state following oral administration)
Prazo: up to day 12 post treatment
up to day 12 post treatment
RAUCτ,ss,M/P (ratio of AUCτ,ss of the BI 600957 to AUCτ,ss of BI 671800)
Prazo: up to day 12 post treatment
up to day 12 post treatment
RCmax,ss,M/P (ratio of Cmax,ss of the BI 600957 to Cmax,ss of BI 671800)
Prazo: up to day 12 post treatment
up to day 12 post treatment
accumulation ratios RA,Cmax
Prazo: up to day 12 post treatment
up to day 12 post treatment
accumulation ratios RA,AUC
Prazo: up to day 12 post treatment
up to day 12 post treatment
peak-trough fluctuation (PTF) of BI 671800
Prazo: up to day 12 post treatment
up to day 12 post treatment
peak-trough fluctuation (PTF) of BI 600957
Prazo: up to day 12 post treatment
up to day 12 post treatment
linearity index (LI) of BI 671800 in plasma
Prazo: up to day 12 post treatment
up to day 12 post treatment

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo

1 de outubro de 2010

Conclusão Primária (Real)

1 de dezembro de 2010

Datas de inscrição no estudo

Enviado pela primeira vez

29 de setembro de 2010

Enviado pela primeira vez que atendeu aos critérios de CQ

6 de outubro de 2010

Primeira postagem (Estimativa)

7 de outubro de 2010

Atualizações de registro de estudo

Última Atualização Postada (Estimativa)

1 de novembro de 2013

Última atualização enviada que atendeu aos critérios de controle de qualidade

31 de outubro de 2013

Última verificação

1 de outubro de 2013

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 1268.59
  • 2009-016369-27 (Número EudraCT: EudraCT)

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever